Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the long-term safety, tolerability and pharmacokinetics of givosiran (ALN-AS1) in AIP patients who completed study ALN-AS1-001 (NCT02452372).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02949830
Study type Interventional
Source Alnylam Pharmaceuticals
Contact
Status Completed
Phase Phase 1/Phase 2
Start date October 2016
Completion date November 5, 2021

See also
  Status Clinical Trial Phase
Terminated NCT02922413 - Panhematin for Prevention of Acute Attacks of Porphyria Phase 2
Completed NCT02943213 - Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride Phase 1
Completed NCT02082860 - Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria Phase 1
Completed NCT03338816 - ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) Phase 3
Completed NCT02452372 - A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) Phase 1
Completed NCT00418795 - Porphozym in the Treatment of Acute Attacks in AIP Phase 2/Phase 3
Active, not recruiting NCT01617642 - Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
Completed NCT02076763 - Observational Study of Acute Intermittent Porphyria Patients N/A
Active, not recruiting NCT02935400 - Acute Porphyria Biomarkers for Disease Activity